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ABSTRACT
Background For patients with psychiatric illnesses
remaining refractory to ‘standard’ therapies,
neurosurgical procedures may be considered. Guidelines
for safe and ethical conduct of such procedures have
previously and independently been proposed by various
local and regional expert groups.
Methods To expand on these earlier documents,
representative members of continental and international
psychiatric and neurosurgical societies, joined efforts to
further elaborate and adopt a pragmatic worldwide set
of guidelines. These are intended to address a broad
range of neuropsychiatric disorders, brain targets and
neurosurgical techniques, taking into account cultural
and social heterogeneities of healthcare environments.
Findings The proposed consensus document highlights
that, while stereotactic ablative procedures such as
cingulotomy and capsulotomy for depression and
obsessive-compulsive disorder are considered
‘established’ in some countries, they still lack level I
evidence. Further, it is noted that deep brain stimulation
in any brain target hitherto tried, and for any psychiatric
or behavioural disorder, still remains at an investigational
stage. Researchers are encouraged to design randomised
controlled trials, based on scientiﬁc and data-driven
rationales for disease and brain target selection.
Experienced multidisciplinary teams are a mandatory
requirement for the safe and ethical conduct of any
psychiatric neurosurgery, ensuring documented
refractoriness of patients, proper consent procedures that
respect patient’s capacity and autonomy, multifaceted
preoperative as well as postoperative long-term follow-
up evaluation, and reporting of effects and side effects
for all patients.
Interpretation This consensus document on ethical
and scientiﬁc conduct of psychiatric surgery worldwide is
designed to enhance patient safety.
BACKGROUND
The majority of patients affected by psychiatric dis-
orders can be managed effectively by means of
pharmacological therapies, psychotherapy and in
some cases, more technical interventions such as
electroconvulsive therapy. These evidence-based
treatments may be used either alone or in combin-
ation. However, a substantial minority of patients
either does not respond, fails to sustain response or
experiences unacceptable adverse effects. It is for
these patients, who are even more at risk with non-
treatment, that the use of neurosurgical procedures
such as stereotactic focal ablative surgery or deep
brain stimulation (DBS) may be considered.
12Case
reports, case series and small-scale clinical trials of
neurosurgical interventions have been reported in
patients with obsessive-compulsive disorder (OCD),
major depressive disorder (MDD), substance abuse/
addiction and anorexia nervosa, among others.
The published experience of DBS for these con-
ditions would appear to have intuitive appeal since
DBS is both adjustable and in most cases reversible
in contrast to stereotactic ablative techniques. DBS
nonetheless requires an invasive implantation of a
permanent device in the brain, with the inherent
risks of the surgical procedure and the burden of
managing, maintaining and replacing the device.
Until scientiﬁcally proven otherwise, DBS is not
superior to ablative surgery for psychiatric disor-
ders. Clinical studies in this ﬁeld may provide an
unprecedented opportunity for fundamental work
with regard to examining disease pathophysiology
and the mechanisms of action of these therapies.
3
METHODS
The Committee for Neurosurgery for Psychiatric
Disorders, as part of the World Society for
Stereotactic and Functional Neurosurgery (WSSFN)
and the European Society for Stereotactic and
Functional Neurosurgery (ESSFN), partnering with
the Working Group ‘Deep Brain Stimulation in
Psychiatry: Guidance for Responsible Research and
Application’, along with the Psychiatric
Neurosurgery Committee of the American Society
for Stereotactic and Functional Neurosurgery
(ASSFN), the Latin American Society for Stereotactic
and Functional Neurosurgery (SLANFE), the
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NeurosurgeryAsian-Australasian Society for Stereotactic and Functional
Neurosurgery (AASSFN) and the World Psychiatric Association
(WPA), propose an expanded set of guidelines to articulate a con-
sensus summary of clinical research standards that are applicable
to testing of DBS and ablative neurosurgery in addition to other
emerging neurosurgical interventions for neuropsychiatric
disorders.
The need for such consensus of guidelines was ﬁrst identiﬁed
by the Committee for Neurosurgery for Psychiatric Disorders
(WSSFN) in early 2011. Then the ﬁrst text was drafted and
revised by HW and BN, respectively, based on literature review.
MH provided an important part of the references. This text was
presented by BN to the Working Group ‘Deep Brain
Stimulation in Psychiatry: Guidance for Responsible Research
and Application’ for further in-depth discussion, leading to a
very extensively modiﬁed version of the previous text.
Afterwards, it was distributed internally by BN among represen-
tatives of different international societies (WSSFN, ESSFN,
ASSFN, SLANFE, AASSFN and WPA), from whom remarks
were received, leading to an optimised consensus text, which
was ﬁnally approved and endorsed by the representatives of the
different societies in late 2011/early 2012.
The guidelines for neurosurgery for psychiatric disorders pre-
sented in this document recognise the Declaration of Helsinki,
issued by the World Medical Association in 1964, amended
several times, as the fundamental document in the ﬁeld of ethics
in biomedical research.
The following guidelines are built directly upon the core ele-
ments of previously published guidelines, reviews, correspon-
dences and legislation from expert neurosurgical, neurological,
psychiatric and neuroethics groups, and health administrations
around the world with an interest in the practice of neurosur-
gery for psychiatric disorders. We have adopted a pragmatic
view in deﬁning a set of guidelines that attempt to serve the
range of neuropsychiatric disorders and, crucially, the cultural
and religious diversity and heterogeneity of healthcare environ-
ments of the international collaborative partners engaged in
these endeavours. The guidelines represent a shared attempt to
articulate these norms at this time. We appreciate that views can
and will evolve over time; therefore, we encourage and
welcome the start of an iterative process. The consensus group
wishes to emphasise the potential importance of neurosurgical
interventions in the future management of psychiatric disorders.
These guidelines are not meant to inhibit, but rather to guide
ethical and effective research in order to facilitate proper devel-
opment of promising therapies. They represent an international
multidisciplinary consensus on best ethical practices, norms and
professional behaviours both in clinical and research settings.
The scope of neurosurgical interventions
for psychiatric disorders
Neurosurgical therapies for psychiatric disorders range from those
that have been in routine use in specialist centres for several
decades (eg, anterior cingulotomy for MDD, anterior capsulotomy
for OCD), to those that remain highly experimental and have only
been tested in very small number of patients (eg, DBS for anorexia
nervosa). However, despite the lengthy history and the weight of
publications, associated with lesion procedures in particular, the
accumulated evidence supporting the application of all neurosurgi-
cal treatments for psychiatric disorders requires to be strength-
ened. While certain procedures are considered to represent
‘established’ practice for severe, treatment-refractory psychiatric
disorders in some countries (eg, radiofrequency anterior capsulot-
omy for severe, treatment-refractory OCD in Belgium, thermal
anterior cingulotomy for MDD and OCD in the USA, Scotland,
South Korea and elsewhere), the nature of these and many other
procedures in neurosurgery, including DBS for psychiatric disor-
ders, remains at a ‘proof-of-principle’ investigational stage of
development.
4
Current practised stereotactic ablative procedures do not have
level I evidence with randomised controlled trials, but their
safety and efﬁcacy are supported by level II evidence in
treatment-refractory MDD and OCD. However, this degree of
evidence is not yet available for ‘new’ lesioning methods such as
gamma knife and stereotactic-focused ultrasound.
In this delicate ﬁeld of neurosurgery for psychiatric disorders,
it seems reasonable to state the following requirement before
the surgical intervention can be stated as ‘approved therapy’.A t
least two blinded (if possible) randomised controlled clinical
trials from two different groups of researchers need to be pub-
lished, both showing an acceptable risk–beneﬁt ratio, at least
comparable with other existing therapies.
Furthermore, there is a resurgence of ablative procedures in
resource-poor contexts, where access to medication, psychother-
apy and more expensive neurosurgical interventions like DBS is
limited. Ablative surgery also becomes an alternative in cases
where a DBS procedure has failed to control the patient’s symp-
toms or where DBS or other neuromodulatory strategies are
inappropriate or impractical.
We encourage researchers to design independent, randomised
and blinded (where possible) controlled trials, with the least
possible conﬂict of interest and bias, to strive towards the gener-
ation of level I (U.S. Preventive Services Task Force) or level A
(U.K. National Institute of Clinical Excellence (NICE) and the
Scottish Intercollegiate Guidelines Network (SIGN)) clinical evi-
dence with regard to neurosurgical procedures for psychiatric
disorders. Unfortunately, different organisations use different
systems to grade evidence and recommendations. Therefore, a
new system—called GRADE—is gaining more acceptance inter-
nationally to establish the quality of evidence and the strength
of recommendation.
5 Robust, data-driven, evidence-based ratio-
nales for disease and brain target selection are required. They
will provide further protection of patients’ safety, improve clin-
ical choice and outcomes, and provide the basis for studies of
disease mechanisms.
3 Further, prior to proceeding to selection
of a new brain target or disease, consultation with peers in the
ﬁeld is strongly recommended. High-quality pilot studies, hon-
estly reported with details and accuracy, have usually allowed
the generation of new discoveries and can pave the way for
bigger clinical trials. The point here is not to blame controlled
trials, but to underline that sometimes small pilot studies can be
used to guide and prepare larger, international clinical trials by
providing preliminary data that will avoid ﬁshing expedition
(eg, for the choice of targets and parameters of stimulation).
Involvement of ethics committees and institutional
review boards
An independent Ethics Committee or Institutional Review
Board (IRB) must have ethical and regulatory oversight for all
investigational neurosurgery for psychiatric disorders. These
committees, in tandem with local and national regulatory agen-
cies, such as the Food and Drug Administration (FDA) in the
USA, the European Medicines Agency (EMA) in the European
Union and their counterparts worldwide, must review and
oversee all aspects of the investigational protocol. Special atten-
tion must be paid to the process of informed consent, avoidance
of therapeutic misconception, proportionality in research, the
assessment of investigative teams, as well as independent experts
1004 Nuttin B, et al. J Neurol Neurosurg Psychiatry 2014;85:1003–1008. doi:10.1136/jnnp-2013-306580
Neurosurgeryfor the interdisciplinary composition necessary to conduct this
work.
6 Particular care is required in cases involving vulnerable
populations (eg, children, those in hierarchical relationships
such as military members, students and prisoners) and in cases
of surrogate decision making when one makes decisions for
others.
78Ethical norms that govern these decisions should
reﬂect the patient/subject’s prior wishes, if they are known, and
be in their best interest. For complex cases, functional neurosur-
geons, together with members of the psychiatric team, should
seek expert bioethics consultation.
A critical distinction must be made for all psychiatric neuro-
surgery, be it ablative or DBS, whether the intervention has
reached therapeutic status or remains investigational. Regulation
of the former should be handled as clinical practice and the
latter as research, requiring discrete oversight, including a Data
Safety Monitoring Board (DSMB) when indicated. Investigators
should be careful not to prematurely designate an investigational
intervention as the standard of care, based on historic precedent
or on limited data, and should seek the advice and guidance of
ethics bodies to avoid idiosyncratic practices.
Preoperative evaluation and patient selection criteria
All candidates for neurosurgery for psychiatric disorders should
meet generally accepted clinical criteria for severity, chronicity,
disability and treatment refractoriness.
9 A comprehensive pre-
operative assessment by independent experts in the management
of psychiatric disorders ensures that all candidates meet rigorous
inclusion and exclusion criteria.
10 Although asking advice from
independent experts is not common practice in medicine and is
difﬁcult to install as a mandatory process worldwide, it has
proven to be of value.
11 Evaluations should use standardised
rating scales,
10 including scales rating disability and quality of
life. The deﬁnition of treatment refractoriness will vary by dis-
order.
4 The suicide risk should be taken into account in all indi-
viduals participating in neurosurgery for psychiatric disorders
before surgery.
4 All patients should complete a preoperative
neuropsychological assessment that includes an evaluation of
the patient’s current cognitive abilities, psychiatric status, per-
sonality and interpersonal functioning, goals and expectations
of surgery, treatment adherence and level of family or other psy-
chosocial support.
12
There should be documentation of failure (eg, due to disab-
ling side effects or lack of efﬁcacy) or limited response to trials
of available standard therapies with adequate dose and duration
(eg, pharmacotherapy, behavioural or cognitive therapy, electro-
convulsive therapy).
13 14 There should be no other reasonable,
evidence-based and less intrusive alternatives available, taking
into account the aggregate risks, beneﬁts and side effects of the
proposed intervention.
13 Furthermore, there should be little
hope for spontaneous recovery and a potential for meaningful
recovery after surgery.
13
Treating the patient remains the primary aim of clinical
research. Indeed, the fact that, for example, DBS is in general
reversible and opens windows to the brain should not be used
ﬁrst for answering an exciting physio-pathological question,
while using the clinical aim only as a pretext.
Decision-making capacity, autonomy and informed consent
Informed consent must be obtained from competent patients.
This requires an explanation of the risks, beneﬁts and alterna-
tives, as well as a context of the individuals’ free choice. Risks
are not only limited to known surgical risks but can include
unknown risks associated with stimulation, ablation or other
forms of modulation at novel sites. The risks of treatment must
also be placed in a clinical context and balanced against the
risks of no treatment. The consent process should include dis-
cussion of what is and is not known of the long-term conse-
quences of neurosurgery for psychiatric disorders.
4 It should be
explained clearly that neurosurgery for psychiatric disorders is
only one aspect of a comprehensive treatment programme that
should continue after surgery.
4 The patient should understand
that neurosurgery for psychiatric disorders aims for a symptom-
atic treatment of psychiatric impairments, but may not be able
to ‘cure’ the disease process.
1
A. An assessment of the patients’ decision-making capacity to
consent should be carried out for each potential subject in
early phase studies of neurosurgery for psychiatric disor-
ders.
4 The methods used should take into account the
potential confounds of psychiatric symptoms.
4 Desperation
can lead to decisions in a hurry, in favour of surgery.
15
Decisional capacity may change over the course of illness or
treatment, like in depression, and therefore should be regu-
larly assessed.
15 For patients to have decisional capacity, they
must satisfy the following three criteria:
▸ Sufﬁcient comprehension of the importance of the pro-
tected personal spheres (physical and mental) into
which a neurosurgical intervention intrudes and of the
scope and risk of the intervening clinical measures.
▸ Sufﬁcient judgement, that is, the ability to assess the con-
sequences of the intervention in light of one’so w n
matters and interests.
▸ Sufﬁcient ability to take self-governed decisions, that is,
the basic capability to decide and act according to
one’s own insights and judgements.
B. The provision of ‘care’ to competent individuals, with the
capacity to consent, without informed consent, is a violation
of ethical norms and disrespectful of personhood.
C. It is acceptable to obtain surrogate consent when the indi-
vidual lacks decision-making capacity. Such use of surrogate
decision-makers should represent extremely rare cases. It
requires special vigilance as surrogates may, on purpose or
unknowingly, pursue their own interests at the expense of
the patient.
16 Local legislation may govern such clinical
situations in different countries.
17 18 In general, patients
who cannot give their own free and informed consent
should not be considered candidates for psychiatric neuro-
surgery unless there is a legally authorised representative
and speciﬁc laws governing such situations.
An example where a surrogate decision-maker may intervene
could be a person with extremely low IQ with extreme autoag-
gression. There are known cases who perform laparotomy on
themselves or pull out one eye and the second eye is in danger.
If no other therapy would help, one may think of a neurosurgi-
cal procedure that decreases the likelihood of extreme autoag-
gression. But even in this life-threatening case a surrogate
decision-maker only comes into play when every effort has been
made to obtain a positive consent from the patient.
D. Patient consent should be maintained and monitored
throughout the neurosurgery for psychiatric disorders
process, and patients must be free to halt their participation
voluntarily.
9
Experienced multidisciplinary team
Neurosurgery for psychiatric disorders should not be decided
by, nor performed by, an individual in isolation and acting alone
regardless of specialty. These procedures require an expert
multidisciplinary team that includes trained stereotactic and
functional neurosurgeons, working in a team with psychiatrists,
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Neurosurgeryneurologists and neuropsychologists. The team should be specia-
lised in the various target disorders and be able to provide com-
prehensive care.
19 Neurosurgeons should use modern, current
standard techniques such as MRI and computerised stereotactic
planning software. It is a neurosurgeons’ important responsibil-
ity to check and maintain accuracy and reliability of the stereo-
tactic system. Postoperative imaging is mandatory (eg, for
documentation of the electrode position or place and extent of
the lesion).
The composition of the team should be adjusted to the dis-
order and may involve a neuroethicist, depending on the idio-
syncratic demands of the work.
6 Ancillary specialists may also
be incorporated into these teams to provide expertise in social
work, rehabilitation, psychotherapy and vocational training. For
best protection of public and profession, members of multidis-
ciplinary neurosurgical groups should monitor their colleagues
to ensure that all members adhere to the proposed guidelines.
It is mandatory to reach a complete consensus with regard to
patient selection, preoperative evaluation and neurosurgical
therapy among neurosurgeons, psychiatrists and other members
of the team as a sine qua non condition. In case of disagree-
ment, any member of the team should not act alone, and
outside expert evaluation should be sought.
Legitimate therapeutic indications
We agree with the landmark 1977 US National Commission
Report on Psychosurgery: “The Commission afﬁrms that the use
of psychosurgery for any purpose other than to provide treat-
ment to individual patients would be inappropriate and should
be prohibited. (Italics in original) Accordingly, the Commission
is recommending safeguards that should prevent the perform-
ance of psychosurgery for purposes of social or institutional
control or other such misuse.”
20 21
Neurosurgery for psychiatric disorders should never be per-
formed for political, law enforcement or social purposes, but
with therapeutic intent aimed at the restoration of normal func-
tion and amelioration of distress and suffering.
91 3
These patients may come from a challenging socioeconomic
background. However, they should not be deprived of, nor
given, a lesser opportunity to participate in cutting-edge
research that may have an important impact in the treatment of
their condition. This research should be available to all patients
irrespective of race, ethnicity, gender, class, religion, sexual
orientation or any other potential cause for bias.
Conﬂicts of interest
The potential for ethical conﬂicts of interest exists because this
work is often reliant upon collaborations between academia,
industry and the clinic.
3 Even though device-related or biothera-
peutic companies may economically support a clinical study to
beneﬁt the interests of patients, it is undeniable that a legitimate
commercial interest in making a proﬁt coexists. In consequence,
there is a potential risk that this aspect may hamper the trans-
parency of the study.
22
Patients and/or their legally authorised representatives should
be made fully aware of the potential conﬂicts of interest in all
informed consent discussions.
9 Investigators should be transpar-
ent with disclosures of ﬁnancial conﬂicts of interests, including
(but not limited to) corporate relationships, consulting fees,
honoraria, research funding and intellectual property rights.
This information should be shared with prospective participants
or their surrogates, colleagues, institutional ofﬁcials and regula-
tors as required by local laws and professional norms.
Investigators with potential conﬂicts of interest should not be
precluded categorically from doing research if the conﬂict is
properly and impartially managed.
3
Postoperative evaluation and long-term follow-up
The ethical principle of non-abandonment obliges clinicians to
follow all patients/subjects longitudinally or until proper transfer
of care to a qualiﬁed clinician occurs. This provision of ongoing
care is especially important because specialty care is not rou-
tinely available in the community.
21 23
A. All patients initially enrolled in any treatment programme or
clinical trial for neurosurgery for psychiatric disorders
should complete comprehensive postoperative assessments,
including neurological, psychiatric and neuropsychological
evaluations, and should be followed up regularly.
10 24 25
B. Clinical research teams should report on the outcome for all
patients, including failed or withdrawn cases, as is manda-
tory in any scientiﬁc report.
24 Patient trust to enrol in such
trials requires that all efforts be made to collect as many sci-
entiﬁc data as reasonably possible to not only determine
safety and clinical efﬁcacy, but to understand the ‘therapy’
and the reason for the resulting outcomes. This includes the
use of multiple clinical ratings and objective scientiﬁc mea-
sures, such as functional imaging, wherever possible.
C. In addition to disease-speciﬁc symptom outcomes, outcomes
in domains such as activities of daily living, cognition,
quality of life and global improvement (including family and
patient perception) should be considered.
4 Social adjustment
following neurosurgery may be challenging for many
patients.
1
D. Research and clinical protocols should include support for
long-term safety and efﬁcacy studies on neurosurgery for
psychiatric disorders for at least 5–10 years of follow-up.
4
Regulatory agencies should require that device manufac-
turers collect long-term follow-up data on safety and
efﬁcacy.
4
E. It should not be considered inherently problematic that
neurosurgical interventions have the potential to cause per-
sonality changes. In view of the fact that many psychiatric
disorders may bring about undesirable changes of a patient’s
personality, it can even be the intended outcome of such
interventions to modify personality by undoing the patho-
logical changes.
26 However, all psychiatric and non-
psychiatric side effects should be documented.
27
F. An independent registry, at this moment not yet available,
should ideally include de-identiﬁed data on all individuals
undergoing neurosurgery for psychiatric disorders.
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